Your session is about to expire
← Back to Search
VITAL Trial Summary
This trial is testing whether a vaccine made from a person's own tumor cells can help keep ovarian cancer from coming back.
- Ovarian Cancer
- Ovarian Tumors
VITAL Trial Eligibility Criteria
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
VITAL Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
VITAL Trial Design
Find a Location
Who is running the clinical trial?
- You have had cancer that has spread to your brain in the past.You have never had an allergic reaction to taxanes or platinum-based drugs.You have severe heart problems, such as congestive heart failure or unstable angina. You have also had a stroke or heart attack in the last 6 months.
- Group 1: Group A
- Group 2: Group B
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many distinct sites are administering this clinical trial?
"Patients may find this trial at the University of Kentucky in Lexington, GHS Cancer Institute in Greenville and Augusta University in Augusta. Additionally, 33 additional sites are recruiting participants for this research project."
Are there still openings for those wishing to participate in this experiment?
"The clinical trial in question is no longer recruiting participants, as evidenced by the last update being dated May 25th 2022. However, according to information hosted on ClinicalTrials.gov, there are currently 677 other medical trials actively seeking patients."
Has Group A been given the green light from the FDA?
"After considering the available evidence, our team at Power rated Group A's safety a 2 because while there is some data confirming its security, Phase 2 trials do not yet provide proof of efficacy."
Share this study with friends